{"entity":{"id":"nct06471205","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of BL-B01D1 in triple-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer is a phase 2 interventional study registered as NCT06471205 by Sichuan Baili Pharmaceutical Co., Ltd., with 52 participants planned, started 2024-08-02 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1 and PD-1 Monoclonal Antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06471205","url":"https://clinicaltrials.gov/study/NCT06471205"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06471205","phase":"2","setting":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody Combination Therapy in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":52,"outcomes":[]},"route":"/trials/nct06471205/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}